content_image/173877.jpg content_image/173879.jpg content_image/173887.jpg content_image/173878.jpg content_image/173880.jpg content_image/173888.jpg
## Revenues 

($ in millions) 

<img src='content_image/173877.jpg'>

## Operating Margins (%) 

<img src='content_image/173879.jpg'>

## Net Income 

($ in millions) 

<img src='content_image/173887.jpg'>

## Operating Profit 

($ in millions) 

<img src='content_image/173878.jpg'>

## Earnings per Diluted Share ($) 

<img src='content_image/173880.jpg'>

## Free Cash Flow from Operations 

($ in millions) 

<img src='content_image/173888.jpg'>

## CONSOLIDATED COMPANY RESULTS 

For 2013, Core Laboratories posted all-time records for revenue, operating profit, operating margins, net income, and free cash flow. 

Led by increases in international activities, revenues increased 9% to $1,073,500,000, and operating profit grew 12% to $333,400,000, yielding operating margins of 31%. Year-over- year incremental operating margins were almost 40%, indicating Core’s high operating efficiencies, leverage, and scalability. Net income increased 12% to $242,800,000, and EPS increased 16% to $5.28. 

At year’s end, Core’s market capitaliza- tion exceeded $8.5 billion, after touch- ing $9 billion months earlier. The Company went public in 1995 with a market capi- talization of $120,000,000. 

Driving this significant increase in share- holder value is the Company’s focus on generating maximum amounts of free cash flow, Core’s first financial tenet. By selecting projects that generate high returns on our invested capital, the Company’s second financial tenet, Core generates industry-leading rates of free cash. Core’s FCF in 2013 reached an all-time high of $262,700,000 after fully funding the Company’s capital expenditure program of approximately $35,400,000. 

In keeping with Core’s third financial tenet, the Company continued to return excess capital back to its shareholders in 2013 via regular dividends and share 

